512 related articles for article (PubMed ID: 23111181)
1. Argon laser with and without anti-vascular endothelial growth factor therapy for extrafoveal polypoidal choroidal vasculopathy.
Gemmy Cheung CM; Yeo I; Li X; Mathur R; Lee SY; Chan CM; Wong D; Wong TY
Am J Ophthalmol; 2013 Feb; 155(2):295-304.e1. PubMed ID: 23111181
[TBL] [Abstract][Full Text] [Related]
2. Effects of choroidal vascular hyperpermeability on anti-vascular endothelial growth factor treatment for polypoidal choroidal vasculopathy.
Cho HJ; Kim HS; Jang YS; Han JI; Lew YJ; Lee TG; Kim CG; Kim JW
Am J Ophthalmol; 2013 Dec; 156(6):1192-1200.e1. PubMed ID: 24011522
[TBL] [Abstract][Full Text] [Related]
3. Reduced-fluence photodynamic therapy combined with intravitreal bevacizumab for polypoidal choroidal vasculopathy.
Sagong M; Lim S; Chang W
Am J Ophthalmol; 2012 May; 153(5):873-882.e2. PubMed ID: 22265146
[TBL] [Abstract][Full Text] [Related]
4. Photodynamic therapy combined with intravitreal injection of vascular endothelial growth factor antibody for polypoidal choroidal vasculopathy.
Moon SW; Kim MS; Kim ES; Yu SY; Kwak HW
Ophthalmologica; 2011; 225(3):169-75. PubMed ID: 21273795
[TBL] [Abstract][Full Text] [Related]
5. Combined reduced fluence photodynamic therapy and intravitreal ranibizumab for polypoidal choroidal vasculopathy.
Ricci F; Calabrese A; Regine F; Missiroli F; Ciardella AP
Retina; 2012 Jul; 32(7):1280-8. PubMed ID: 22218148
[TBL] [Abstract][Full Text] [Related]
6. Long-term visual outcome and prognostic factors after intravitreal ranibizumab injections for polypoidal choroidal vasculopathy.
Kang HM; Koh HJ
Am J Ophthalmol; 2013 Oct; 156(4):652-60. PubMed ID: 23891333
[TBL] [Abstract][Full Text] [Related]
7. One-year outcomes of intravitreal bevacizumab (avastin) therapy for polypoidal choroidal vasculopathy.
Cheng CK; Peng CH; Chang CK; Hu CC; Chen LJ
Retina; 2011 May; 31(5):846-56. PubMed ID: 21317837
[TBL] [Abstract][Full Text] [Related]
8. Combined photodynamic therapy with intravitreal bevacizumab injections for polypoidal choroidal vasculopathy: long-term visual outcome.
Kang HM; Koh HJ; Lee CS; Lee SC
Am J Ophthalmol; 2014 Mar; 157(3):598-606.e1. PubMed ID: 24269378
[TBL] [Abstract][Full Text] [Related]
9. One-year results of three monthly ranibizumab injections and as-needed reinjections for polypoidal choroidal vasculopathy in Japanese patients.
Hikichi T; Higuchi M; Matsushita T; Kosaka S; Matsushita R; Takami K; Ohtsuka H; Ariga H
Am J Ophthalmol; 2012 Jul; 154(1):117-124.e1. PubMed ID: 22465366
[TBL] [Abstract][Full Text] [Related]
10. Effects of vitreomacular adhesion on anti-vascular endothelial growth factor treatment for polypoidal choroidal vasculopathy.
Cho HJ; Baek JS; Lee DW; Cho SW; Kim CG; Kim JW
Retina; 2013; 33(10):2126-32. PubMed ID: 23609123
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of intravitreal bevacizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy.
Gomi F; Sawa M; Wakabayashi T; Sasamoto Y; Suzuki M; Tsujikawa M
Am J Ophthalmol; 2010 Jul; 150(1):48-54.e1. PubMed ID: 20609707
[TBL] [Abstract][Full Text] [Related]
12. Photodynamic therapy versus combination therapy in polypoidal choroidal vasculopathy: changes of aqueous vascular endothelial growth factor.
Lee MY; Lee WK; Baek J; Kwon OW; Lee JH
Am J Ophthalmol; 2013 Aug; 156(2):343-8. PubMed ID: 23664208
[TBL] [Abstract][Full Text] [Related]
13. Improvement of angiographic findings of polypoidal choroidal vasculopathy after intravitreal injection of ranibizumab monthly for 3 months.
Hikichi T; Ohtsuka H; Higuchi M; Matsushita T; Ariga H; Kosaka S; Matsushita R; Takami K
Am J Ophthalmol; 2010 Nov; 150(5):674-682.e1. PubMed ID: 20691424
[TBL] [Abstract][Full Text] [Related]
14. Relationship between clinical characteristics of polypoidal choroidal vasculopathy and choroidal vascular hyperpermeability.
Koizumi H; Yamagishi T; Yamazaki T; Kinoshita S
Am J Ophthalmol; 2013 Feb; 155(2):305-313.e1. PubMed ID: 23022162
[TBL] [Abstract][Full Text] [Related]
15. Anti-vascular endothelial growth factor monotherapy in the treatment of submacular hemorrhage secondary to polypoidal choroidal vasculopathy.
Cho HJ; Koh KM; Kim HS; Lee TG; Kim CG; Kim JW
Am J Ophthalmol; 2013 Sep; 156(3):524-531.e1. PubMed ID: 23769197
[TBL] [Abstract][Full Text] [Related]
16. Two-year results of photodynamic therapy combined with intravitreal anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy.
Kim M; Kim K; Kim DG; Yu SY; Kwak HW
Ophthalmologica; 2011; 226(4):205-13. PubMed ID: 21893965
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal ranibizumab with or without photodynamic therapy for the treatment of symptomatic polypoidal choroidal vasculopathy.
Lai TY; Lee GK; Luk FO; Lam DS
Retina; 2011 Sep; 31(8):1581-8. PubMed ID: 21610566
[TBL] [Abstract][Full Text] [Related]
18. Real-World Treatment Outcomes of Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy in Asians.
Fenner BJ; Ting DSW; Tan ACS; Teo K; Chan CM; Mathur R; Yeo IYS; Wong TY; Wong EYM; Cheung CMG
Ophthalmol Retina; 2020 Apr; 4(4):403-414. PubMed ID: 31953109
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal bevacizumab for exudative branching vascular networks in polypoidal choroidal vasculopathy.
Wakabayashi T; Gomi F; Sawa M; Tsujikawa M; Nishida K
Br J Ophthalmol; 2012 Mar; 96(3):394-9. PubMed ID: 21719568
[TBL] [Abstract][Full Text] [Related]
20. Two-year course of subfoveal pigment epithelial detachment in eyes with age-related macular degeneration and visual acuity better than 20/40.
Baba T; Kitahashi M; Kubota-Taniai M; Oshitari T; Yamamoto S
Ophthalmologica; 2012; 228(2):102-9. PubMed ID: 22508168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
